Eli Lilly and Company / Analyst ratings
Price targets
Analyst ratings
No analyst ratings available
-
Jefferies maintains Eli Lilly at 'Buy' - target $994
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Eli Lilly with a price target of $994. The US pharmaceutical manufacturer is likely to see slightly weaker business with its diabetes and weight-loss drug Mounjaro in the current quarter than previously expected, analyst Akash Tewari wrote in a report released Friday. While Eli Lilly could reach the lower end of its annual forecast, the gap between its estimates and the market consensus is widening./niw/mis
Publication of the original study: December 20, 2024 / 11:25 AM / ET
First distribution of the original study: December 20, 2024 / 11:25 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies lowers target for Eli Lilly to $994 - 'Buy'
NEW YORK (dpa-AFX Analyst) - The research firm Jefferies lowered its price target for Eli Lilly from $1,113 to $994 following its quarterly results, but maintained its "Buy" rating. The pharmaceutical company significantly missed market expectations for sales of its key diabetes and weight-loss drugs Zepbound and Mounjaro, analyst Akash Tewari wrote in a report released Thursday. It reduced its revenue and earnings forecasts for 2024 and 2025./edh/ajx
Publication of the original study: October 31, 2024 / 6:31 a.m. / ET
First distribution of the original study: October 31, 2024 / 6:31 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.